Clinical Trial Update: Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis [Phase 3]

View source ↗

Summary

Phase 3 trial update comparing Ofatumumab and Siponimod to Fingolimod in pediatric multiple sclerosis for efficacy and safety.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• Fingolimod (fingolimod)
• Ofatumumab (ofatumumab)
• Siponimod (siponimod)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Multiple Sclerosis (MS) | Phase 3 | Status: ACTIVE_NOT_RECRUITING